BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Román E, Mendizábal S, Jarque I, de la Rubia J, Sempere A, Morales E, Praga M, Ávila A, Górriz JL. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option. Nefrologia 2017;37:478-91. [PMID: 28946961 DOI: 10.1016/j.nefro.2017.01.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Galic S, Csuka D, Prohászka Z, Turudic D, Dzepina P, Milosevic D. A case report of a child with sepsis induced multiorgan failure and massive complement consumption treated with a short course of Eculizumab: A case of crosstalk between coagulation and complement? Medicine (Baltimore) 2019;98:e14105. [PMID: 30681570 DOI: 10.1097/MD.0000000000014105] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Schulte-Kemna L, Reister B, Bettac L, Ludwig U, Fürst D, Mytilineos J, Bergmann C, van Erp R, Schröppel B. Eculizumab in chemotherapy-induced thrombotic microangiopathy. Clin Nephrol Case Stud 2020;8:25-32. [PMID: 32318323 DOI: 10.5414/CNCS109836] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Blasco M, Guillén E, Quintana LF, Garcia-Herrera A, Piñeiro G, Poch E, Carreras E, Campistol JM, Diaz-Ricart M, Palomo M. Thrombotic microangiopathies assessment: mind the complement. Clin Kidney J 2021;14:1055-66. [PMID: 33841853 DOI: 10.1093/ckj/sfaa195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 García-martín E, Manrique-rodríguez S, Martínez Fernández-llamazares C, Goicoechea-diezhondino M, Álvarez-blanco O, García-morín M, Sanjurjo-sáez M. Variability in management and outcomes of therapy with eculizumab in atypical hemolytic uremic syndrome. Expert Opinion on Orphan Drugs 2019;7:525-33. [DOI: 10.1080/21678707.2019.1703108] [Reference Citation Analysis]
5 Ávila A, Gavela E, Sancho A. Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity. Front Med (Lausanne) 2021;8:642864. [PMID: 33898482 DOI: 10.3389/fmed.2021.642864] [Reference Citation Analysis]
6 Uriol Rivera MG, Cabello Pelegrin S, Ballester Ruiz C, López Andrade B, Lumbreras J, Obrador Mulet A, Perez Montaña A, Ferreruela Serlavos M, Ayestarán Rota JI, Ferrer Balaguer J, Delgado Sanchez O, Pallares Ferreres L, Mas Bonet A, Picado Valles MJ, de Gopegui Valero RMR. Impact of a multidisciplinary team for the management of thrombotic microangiopathy. PLoS One 2018;13:e0206558. [PMID: 30388144 DOI: 10.1371/journal.pone.0206558] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Allinovi M, Bellinvia A, Pesce F, Milan Manani S, Razzolini L, Brezzi B, Protopapa P, Mantero V, Caroti L, Cirami CL, Amato MP, Del Vecchio L. Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series. Brain Sci 2021;11:1341. [PMID: 34679405 DOI: 10.3390/brainsci11101341] [Reference Citation Analysis]
8 Mira FS, Nunes AL, Elvas AR, Oliveira N. Atypical haemolytic uremic syndrome from multiple missenses to a full-blown disease. BMJ Case Rep 2019;12:e230026. [PMID: 31253663 DOI: 10.1136/bcr-2019-230026] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Palomo M, Blasco M, Molina P, Lozano M, Praga M, Torramade-Moix S, Martinez-Sanchez J, Cid J, Escolar G, Carreras E, Paules C, Crispi F, Quintana LF, Poch E, Rodas L, Goma E, Morelle J, Espinosa M, Morales E, Avila A, Cabello V, Ariceta G, Chocron S, Manrique J, Barros X, Martin N, Huerta A, Fraga-Rodriguez GM, Cao M, Martin M, Romera AM, Moreso F, Manonelles A, Gratacos E, Pereira A, Campistol JM, Diaz-Ricart M. Complement Activation and Thrombotic Microangiopathies. Clin J Am Soc Nephrol 2019;14:1719-32. [PMID: 31694864 DOI: 10.2215/CJN.05830519] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 7.3] [Reference Citation Analysis]
10 Hanna RM, Barsoum M, Vandross A, Kurtz I, Burwick R. Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition. Curr Opin Nephrol Hypertens 2019;28:278-87. [PMID: 30865166 DOI: 10.1097/MNH.0000000000000499] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
11 Figueiredo CR, Escoli R, Santos P, Sofia F, Lopes K. Thrombotic microangiopathy in a patient with systemic lupus erythematosus and anti-factor H autoantibodies. CEN Case Rep 2021. [PMID: 34269998 DOI: 10.1007/s13730-021-00627-5] [Reference Citation Analysis]
12 Chang JC. TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease. Thromb J 2018;16:20. [PMID: 30127669 DOI: 10.1186/s12959-018-0174-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
13 Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Ther Apher Dial 2019;23:4-21. [PMID: 30294946 DOI: 10.1111/1744-9987.12763] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]